BRPI0409789B8 - célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva - Google Patents

célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva

Info

Publication number
BRPI0409789B8
BRPI0409789B8 BRPI0409789A BRPI0409789A BRPI0409789B8 BR PI0409789 B8 BRPI0409789 B8 BR PI0409789B8 BR PI0409789 A BRPI0409789 A BR PI0409789A BR PI0409789 A BRPI0409789 A BR PI0409789A BR PI0409789 B8 BRPI0409789 B8 BR PI0409789B8
Authority
BR
Brazil
Prior art keywords
preparation
nucleic acid
acid molecules
composition
bacterial cell
Prior art date
Application number
BRPI0409789A
Other languages
English (en)
Inventor
Raupach Bärbel
Hess Jürgen
Grode Leander
H E Kaufmann Stefan
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BRPI0409789A publication Critical patent/BRPI0409789A/pt
Publication of BRPI0409789B1 publication Critical patent/BRPI0409789B1/pt
Publication of BRPI0409789B8 publication Critical patent/BRPI0409789B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

vacina de tuberculose com eficácia aperfeiçoada. a presente invenção refere-se a novas vacinas recombinantes provendo imunidade protetora contra tuberculose. ainda, a presente invenção refere-se a novas moléculas de ácido nucléico recombinante, vetores contendo as ditas moléculas de ácido nucléico, células transformadas com as ditas moléculas de ácido nucléico e polipeptídeos codificados pelas ditas moléculas de ácido nucléico.
BRPI0409789A 2003-04-23 2004-04-23 célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva BRPI0409789B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23
PCT/EP2004/004345 WO2004094469A1 (en) 2003-04-23 2004-04-23 Tuberculosis vaccine with improved efficacy

Publications (3)

Publication Number Publication Date
BRPI0409789A BRPI0409789A (pt) 2006-05-30
BRPI0409789B1 BRPI0409789B1 (pt) 2018-10-16
BRPI0409789B8 true BRPI0409789B8 (pt) 2021-05-25

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409789A BRPI0409789B8 (pt) 2003-04-23 2004-04-23 célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva

Country Status (24)

Country Link
US (2) US7988980B2 (pt)
EP (1) EP1618128B1 (pt)
JP (1) JP4662925B2 (pt)
KR (1) KR101101263B1 (pt)
CN (1) CN1798762B (pt)
AT (1) ATE473238T1 (pt)
AU (1) AU2004232485B2 (pt)
BR (1) BRPI0409789B8 (pt)
CA (1) CA2523084C (pt)
CU (1) CU23608A3 (pt)
CY (1) CY1110793T1 (pt)
DE (1) DE602004028000D1 (pt)
DK (1) DK1618128T3 (pt)
ES (1) ES2344698T3 (pt)
HK (1) HK1091217A1 (pt)
HR (1) HRP20100395T1 (pt)
MX (1) MXPA05011360A (pt)
PL (1) PL1618128T3 (pt)
PT (1) PT1618128E (pt)
RU (1) RU2342400C2 (pt)
SI (1) SI1618128T1 (pt)
UA (1) UA91180C2 (pt)
WO (1) WO2004094469A1 (pt)
ZA (1) ZA200508276B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE473238T1 (de) * 2003-04-23 2010-07-15 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz
EP1649869A1 (en) 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
ZA200704765B (en) 2004-12-01 2008-09-25 Aeras Global Tb Vaccine Found Recombinant BCG strains with enhanced ability to escape the endosome
CN101969976A (zh) * 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
RU2586774C2 (ru) 2010-08-27 2016-06-10 Пантархей Байосайенс Б.В. Иммунотерапевтический способ лечения рака простаты
AU2011304385B2 (en) * 2010-09-20 2015-02-26 Vakzine Projekt Management Gmbh Recombinant Mycobacterium as vaccine for use in humans
WO2012062861A1 (en) 2010-11-10 2012-05-18 Laboratorios Leti, S.L. New adjuvant
PL2654783T3 (pl) * 2010-12-21 2017-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinowane Mycobacterium jako szczepionka
BR112013015878B1 (pt) * 2010-12-21 2020-10-27 Vakzine Projekt Management Gmbh método para determinação da eficácia de uma vacina e kit de reagentes
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
RU2760580C2 (ru) * 2017-04-07 2021-11-29 Ченду Йоньгань Фармасьютикал Ко., Лтд. РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR
CN111133412A (zh) * 2017-07-25 2020-05-08 奥罗拉实验室有限公司 基于工具链构建车辆ecu软件的软件增量更新和异常检测
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228768A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
IL310225A (en) 2021-07-22 2024-03-01 Serum Life Science Europe Gmbh Recombinant MYCOBACTERIUM as an immunotherapeutic agent for the second-line treatment of bladder carcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
ATE473238T1 (de) * 2003-04-23 2010-07-15 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz

Also Published As

Publication number Publication date
EP1618128B1 (en) 2010-07-07
CA2523084A1 (en) 2004-11-04
US20070134267A1 (en) 2007-06-14
RU2005136354A (ru) 2006-03-20
UA91180C2 (ru) 2010-07-12
ZA200508276B (en) 2006-06-28
US20120027794A1 (en) 2012-02-02
US8545854B2 (en) 2013-10-01
PL1618128T3 (pl) 2010-12-31
BRPI0409789A (pt) 2006-05-30
JP4662925B2 (ja) 2011-03-30
JP2007524367A (ja) 2007-08-30
KR20050114281A (ko) 2005-12-05
CY1110793T1 (el) 2015-06-10
RU2342400C2 (ru) 2008-12-27
CN1798762B (zh) 2010-04-28
US7988980B2 (en) 2011-08-02
PT1618128E (pt) 2010-10-13
ATE473238T1 (de) 2010-07-15
HK1091217A1 (en) 2007-01-12
AU2004232485A1 (en) 2004-11-04
SI1618128T1 (sl) 2010-11-30
KR101101263B1 (ko) 2012-01-04
HRP20100395T1 (hr) 2010-09-30
MXPA05011360A (es) 2005-11-28
CA2523084C (en) 2012-09-04
WO2004094469A1 (en) 2004-11-04
DK1618128T3 (da) 2010-10-18
CU23608A3 (es) 2010-12-08
CN1798762A (zh) 2006-07-05
BRPI0409789B1 (pt) 2018-10-16
EP1618128A1 (en) 2006-01-25
DE602004028000D1 (de) 2010-08-19
ES2344698T3 (es) 2010-09-03
AU2004232485B2 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
BRPI0409789B8 (pt) célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva
DK2566507T3 (da) Biokonjugatvacciner med kapselformige grampositive bakterier
BR112015005674A2 (pt) variantes e métodos de uso de hppd
MX2011011186A (es) Una vacuna antituberculosis tb para evitar la reactivacion.
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
AR065076A1 (es) Vacuna contra el papilomavirus
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
ATE522541T1 (de) Bakterielle adhäsine konformere
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
CO6260102A2 (es) Cepas de mycoplasma gallisepticum atenuadas
WO2008056174A3 (en) Novel compositions and uses thereof
DE602004028029D1 (en) Rwendung
AR092630A1 (es) Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
RU2012126328A (ru) Вакцина против пневмонии, вызываемой streptococcus pneumoniae, на основе гибридного белка
BRPI0518109A (pt) cepa bacteriana, nucleocapsìdeo, preparação de vacina, método para criar uma bactéria recombinante, bactéria mutante, seqüências de rna fluorado para deslanchar rdsrna e meio para eletroporação
NZ603854A (en) West nile virus vaccine
AR041086A1 (es) Vacuna
WO2004085466A8 (en) Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
AR088176A1 (es) Secuencias de aminoacidos para el control de patogenos
DE60143810D1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
TW200801034A (en) Novel sea lice vaccine
NZ614064A (en) Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
Lahiri et al. New tricks new ways: exploitation of a multifunctional enzyme arginase by pathogens
UA112297C2 (uk) Рекомбінантна мікобактерія як вакцина для застосування на людях

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF